The teratogenic risks of antiseizure medications (ASMs) have been a concern since the first reports more than 50 years ago of an association between maternal use of ASMs and occurrence of birth defects in offspring.1 The risks and possible differences in risks between ASMs have become a major factor in treatment decision and in particular drug selection for girls and young women with epilepsy.2 Although the initial focus was on anatomical teratogenicity (ie, malformations), more attention has been given during the last 2 decades to the possibility that exposure to ASMs during fetal life may adversely affect the neurodevelopment of the offspring. A landmark study by Meador et al3 showed that exposure to high doses of valproate was associated with lower IQ in children at 6 years of age compared with children whose mothers had been treated with phenytoin, carbamazepine, or lamotrigine. The results of this carefully designed cohort study have been confirmed in other similar studies.4 Large population health care register–based studies have subsequently expanded our understanding of the adverse effects of maternal use of valproate on the neurodevelopment of the exposed child. Hence, in nationwide population-based studies, valproate exposure has been associated with a 2- to 5-fold increased risk of autism and autism spectrum disorders,5,6 a 1.5- to 1.7-fold increased risk of attention-deficit/hyperactivity disorder,6,7 a 4- to 5-fold increased risk of intellectual disabilities,8 and a 3- to 5-fold increased risk of early neurodevelopmental disorders.9
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Tomson T, Bromley R. Association of Fetal Exposure to Newer Antiseizure Medications With Neurodevelopment: A Step Toward a Better Understanding. JAMA Neurol. Published online June 07, 2021. doi:10.1001/jamaneurol.2021.1217
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: